InfertilityLLLTNCT02764034
Effect of Low Level Laser Therapy on Endometrial Cells: An In Vitro Study
A study testing Low level Laser diode machine in people with Infertility, run by Cairo University at 1 site in Egypt.
Trial summary
The human endometrium is an extremely sensitive target. LLLT can enhance the proliferation rate of various cell lines, it produces higher rates of ATP, RNA, and DNA synthesis in stem cells and other cell lines. Thus, LLLT improves the proliferation of the cells without causing any cytotoxic effects. Read more about this study
- Who is it for?
- Ages 20 to 38 years, women only
- Conditions the study is for
- Infertility
- What is being tested?
- Low level Laser diode machine
- Type of treatment
- Medical device
- How many people
- Not given
- Where
- 1 siteEgypt
- Study dates
- Start not givento not given
- Phase
- Expanded access
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 38 years
- Women only
- No healthy volunteers
- Adult
Who may be able to join
- Demographic:
- Women in child bearing period aging from 20 to 38 years.
- Only women up to 38 years will be included, to remove advanced age as a confounding factor that could affect the study results.
- BMI: > 20 and < 35 " BMI more 35 is excluded to remove any confounding factor related to increased BMI form the study"
- Human endometrial sample will be obtained from infertile women with the following conditions:
- Recurrent IUI, IVF or ICSI Failure without any clear cause.
- Women with unexplained infertility after exclusion of all other causes of infertility and exclusion of male factor.
Who cannot join
- Women with endometrial cancer or precancerous lesions.
- Women with any malignancy of the genital tract as vulval, vaginal, cervical, ovarian and other malignancies.
- Women undergoing dilatation and curettage due to the following conditions will be excluded:
- Any pregnancy related pathology (eg, incomplete abortion, missed abortion, septic abortion, induced pregnancy termination, treatment and evaluation of gestational trophoblastic disease).
- Dilatation and curettage for dysfunctional uterine bleeding; irregular bleeding or menorrhagia
- Hormonal treatment or any medication that may affect the endometrium, including any patient received hormonal therapy in the 3 months preceding the study.
- Before endometrial ablation for treatment of endometrial hyperplasia or perimenopausal bleeding.
- Tissues with proved precancerous or neoplastic changes in the endometrial sample will be discarded and eliminated before initiation of the study.
Trial locations and contacts
1 site in 1 country.
Egypt1 site
- Available
National Research Centre
Cairo, El Dokki, 002
Osama M. Azmy, MD, FRCOG, 01223103084 ext. 002, osamaazmy@yahoo.com
Ghada M. Nour El Din, MD, 01007196882 ext. 002, genoghada@ymail.com
About this study
Official title: Low Level Laser Therapy to Endometrial Cells: A Novel Approach to Increase Endometrial Proliferation and Enhance Endometrial Receptivity
The human endometrium is an extremely sensitive target. LLLT can enhance the proliferation rate of various cell lines, it produces higher rates of ATP, RNA, and DNA synthesis in stem cells and other cell lines. Thus, LLLT improves the proliferation of the cells without causing any cytotoxic effects.
The aim of this work is to assess the ability of low level laser therapy in enhancing endometrial proliferation and increasing endometrial receptivity.
A number of 120 human endometrial samples will be studied, and will be collected from 40 infertile women attending the infertility clinic at NRC. Each human endometrial sample will be divided into 3 plates, in order to establish 3 main groups of 40 culture plates for single laser exposure group versus 40 culture plates for multiple laser exposure group and 40 tissue culture plates for control samples, thus a total of 120 tissue culture plates will be studied, the study groups will be exposed to low level laser therapy and compared to their matched controls.. Assessment of number and size of cells after LLLT as a marker of normal proliferation and b) The expression of Integrin aVB3 "alpha v B3", MUC-1 and LIFand the development of pinopodes on the surface of epithelial cells as markers of endometrial receptivity and the detection of PTEN tumor suppressor gene as a marker of abnormal proliferation or premalignant condition will be performed to assess the effect of LLLT on the endometrial cell culture. This study might offer a new therapeutic modality which might increase endometrial thickness and enhance receptivity .
Read the detailed description
Plan of work:
A number of 40 human endometrial samples will be collected from 40 infertile women attending the infertility clinic at the National Research Center (each sample will be divided into 3 culture plates; single exposure group, multiple exposure group and control group) and will be included in the study.
Each human endometrial sample will be divided into 3 plates, in order to establish 3 main groups of 40 culture plates for single laser exposure group versus 40 culture plates for multiple laser exposure group and 40 tissue culture plates for control samples, thus a total of 120 tissue culture plates will be studied, the study groups will be exposed to low level laser therapy and compared to their matched controls.
Timing of endometrial tissue sample:
Endometrial tissue biopsy will be performed in the early proliferative phase just after menstruation ceases (from day 5 to day8).
Consent A written informed consent will be obtained from each woman before the procedure. The consent will explain the purpose from the procedure, the aim from the research and the possible side effects.
Endometrial cell culture:
Endometrial biopsy strips will be collected from women included in the study. The endometrial biopsy strips will be taken from the uterine wall using pipelle.
Endometrial tissue will be transported to the laboratory in isolation media. Endometrial tissue will be stored at 4°C, and processed within 2-10 h.
Clusters of cells will be considered colonies when they become visible macroscopically and contain greater than 50 cells.
The same culture condition will be applied to both study and control samples. The tissue culture will be discarded after 14 days when the study will be completed.
Low level laser therapy will be wavelength 635nm diode laser, power of 40mw will be tested on cultured endometrial cells in Petri dish S.A. of 9.62cm2 with fluence rate of 4.2 J/cm2 in the continuous mode, depth of penetration at 635nm ranges from 1 to 6mm.
Tissue cultures in the study group will be divided into 2 groups; The 1st group will be composed of 40 tissue culture plates and will be exposed to the total fluence dose 4.2 J/cm2 in a single session of 16 minutes duration with low level therapy machine adjusted at power of 40mw. The 2nd group will be composed of another 40 tissue culture plates, they will be exposed to the same fluence rate but in multiple sessions ''3 sessions'', which will be performed every other day, each session will last for approximately 5.34 minutes using low level laser of power of 40mw to reach the same fluence dose of 4.2 J/cm2 after finishing the 3rd session.
Single versus multiple exposures of LLLT will be tested in the endometrial culture plates and will be compared to control group not exposed to laser. Comparison between single session exposure and multiple sessions' exposure is important in order to determine the benefits over the risk of multiple exposures sessions in thin endometrium in vivo, being an invasive procedure and requiring a fibro-optic probe insertion inside the uterus which might cause some discomfort to the patient and could be affected by patient's compliance.
RT-PCR Analysis technique and steps:
Real time PCR will be used to screen and detect the presence of endometrial implantation markers namely the expression of Integrin aVB3 "alpha v B3", MUC-1, LIF and also the expression of PTEN tumor suppressor gene as an early marker for premalignant endometrial disease.
Electron microscopy; Cells in tissue culture will be examined by electron microscope in order to detect the presence of pinopodes as a marker of increased endometrial receptivity.
- Conditions
- Infertility
- Being tested
- Low level Laser diode machine
- Keywords
- Low level Laser, Tissue culture, Endometrial receptivity
- Medical subject headings
- Infertility
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Low level Laser diode machineDevice
wavelength 635 Low level diode laser power control time control Continuous mode
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 May 2016 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for InfertilityStudies of the same condition, open and under way.
- More trials run by Cairo UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Expanded access
Sponsor and investigators
- Lead sponsor
- Cairo University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Doaa Abdelmageed El Faham, National Research Centre, Egypt
- Investigators
- Amr H. El Noury, MD, FRCOG, Study director, Cairo UniversityMarwa A. El Shaer, MD, Study chair, Professor of Pathology at National Research CentreMona I. Morsy, MD, Study director, Lecturer in Molecular Biology in National Institute of Laser and Enhanced ScienceOsama M. Azmy, MD, FRCOG, Study director, Professor of obstetrics and gynecology at National Research Centre
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02764034
- Sponsor's protocol ID
- effect of low level laser 001
- Acronym
- LLLT
- Status last verified
- Jul 2017
- First submitted
- 14 Apr 2016
- Last updated
- 25 Jul 2017
- Results posted
- No
Study at a glance
From the registry record, last updated by the sponsor on 25 Jul 2017. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Low Level Laser Therapy to Endometrial Cells: A Novel Approach to Increase Endometrial Proliferation and Enhance Endometrial Receptivity
- ClinicalTrials.gov ID
- NCT02764034
- Acronym / sponsor ID
- LLLT / effect of low level laser 001
- Conditions
- Infertility
- Keywords
- Low level Laser, Tissue culture, Endometrial receptivity
- Study type
- Expanded access
- Recruitment status
- Available
- Lead sponsor
- Cairo UniversityUniversity, hospital or other
- First posted
- 6 May 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The human endometrium is an extremely sensitive target. LLLT can enhance the proliferation rate of various cell lines, it produces higher rates of ATP, RNA, and DNA synthesis in stem cells and other cell lines. Thus, LLLT improves the proliferation of the cells without causing any cytotoxic effects.
The aim of this work is to assess the ability of low level laser therapy in enhancing endometrial proliferation and increasing endometrial receptivity.
A number of 120 human endometrial samples will be studied, and will be collected from 40 infertile women attending the infertility clinic at NRC. Each human endometrial sample will be divided into 3 plates, in order to establish 3 main groups of 40 culture plates for single laser exposure group versus 40 culture plates for multiple laser exposure group and 40 tissue culture plates for control samples, thus a total of 120 tissue culture plates will be studied, the study groups will be exposed to low level laser therapy and compared to their matched controls.. Assessment of number and size of cells after LLLT as a marker of normal proliferation and b) The expression of Integrin aVB3 "alpha v B3", MUC-1 and LIFand the development of pinopodes on the surface of epithelial cells as markers of endometrial receptivity and the detection of PTEN tumor suppressor gene as a marker of abnormal proliferation or premalignant condition will be performed to assess the effect of LLLT on the endometrial cell culture. This study might offer a new therapeutic modality which might increase endometrial thickness and enhance receptivity .
Detailed description
Plan of work:
A number of 40 human endometrial samples will be collected from 40 infertile women attending the infertility clinic at the National Research Center (each sample will be divided into 3 culture plates; single exposure group, multiple exposure group and control group) and will be included in the study.
Each human endometrial sample will be divided into 3 plates, in order to establish 3 main groups of 40 culture plates for single laser exposure group versus 40 culture plates for multiple laser exposure group and 40 tissue culture plates for control samples, thus a total of 120 tissue culture plates will be studied, the study groups will be exposed to low level laser therapy and compared to their matched controls.
Timing of endometrial tissue sample:
Endometrial tissue biopsy will be performed in the early proliferative phase just after menstruation ceases (from day 5 to day8).
Consent A written informed consent will be obtained from each woman before the procedure. The consent will explain the purpose from the procedure, the aim from the research and the possible side effects.
Endometrial cell culture:
Endometrial biopsy strips will be collected from women included in the study. The endometrial biopsy strips will be taken from the uterine wall using pipelle.
Endometrial tissue will be transported to the laboratory in isolation media. Endometrial tissue will be stored at 4°C, and processed within 2-10 h.
Clusters of cells will be considered colonies when they become visible macroscopically and contain greater than 50 cells.
The same culture condition will be applied to both study and control samples. The tissue culture will be discarded after 14 days when the study will be completed.
Low level laser therapy will be wavelength 635nm diode laser, power of 40mw will be tested on cultured endometrial cells in Petri dish S.A. of 9.62cm2 with fluence rate of 4.2 J/cm2 in the continuous mode, depth of penetration at 635nm ranges from 1 to 6mm.
Tissue cultures in the study group will be divided into 2 groups; The 1st group will be composed of 40 tissue culture plates and will be exposed to the total fluence dose 4.2 J/cm2 in a single session of 16 minutes duration with low level therapy machine adjusted at power of 40mw. The 2nd group will be composed of another 40 tissue culture plates, they will be exposed to the same fluence rate but in multiple sessions ''3 sessions'', which will be performed every other day, each session will last for approximately 5.34 minutes using low level laser of power of 40mw to reach the same fluence dose of 4.2 J/cm2 after finishing the 3rd session.
Single versus multiple exposures of LLLT will be tested in the endometrial culture plates and will be compared to control group not exposed to laser. Comparison between single session exposure and multiple sessions' exposure is important in order to determine the benefits over the risk of multiple exposures sessions in thin endometrium in vivo, being an invasive procedure and requiring a fibro-optic probe insertion inside the uterus which might cause some discomfort to the patient and could be affected by patient's compliance.
RT-PCR Analysis technique and steps:
Real time PCR will be used to screen and detect the presence of endometrial implantation markers namely the expression of Integrin aVB3 "alpha v B3", MUC-1, LIF and also the expression of PTEN tumor suppressor gene as an early marker for premalignant endometrial disease.
Electron microscopy; Cells in tissue culture will be examined by electron microscope in order to detect the presence of pinopodes as a marker of increased endometrial receptivity.
Study design
Who may qualify
- Ages
- 20 to 38 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (7 listed)
- Women in child bearing period aging from 20 to 38 years.
- Only women up to 38 years will be included, to remove advanced age as a confounding factor that could affect the study results.
- BMI: > 20 and < 35 " BMI more 35 is excluded to remove any confounding factor related to increased BMI form the study"
- Human endometrial sample will be obtained from infertile women with the following conditions:
Key exclusion criteria (8 listed)
- Women with endometrial cancer or precancerous lesions.
- Women with any malignancy of the genital tract as vulval, vaginal, cervical, ovarian and other malignancies.
- Women undergoing dilatation and curettage due to the following conditions will be excluded:
- Tissues with proved precancerous or neoplastic changes in the endometrial sample will be discarded and eliminated before initiation of the study.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Low level Laser diode machinewavelength 635 Low level diode laser power control time control Continuous mode | Device | – |
Primary outcome
Not reported in the source record.
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 25 Jul 2017.
- 1\. AlGhamdi KM, Kumar A, Moussa NA (2012). Low-level laser therapy: a useful technique for enhancing the proliferation of various cultured cells. Lasers Med Sci. Vol.27(1), pp.237-249. \[PubMed\]Link provided by the sponsor.
- Barolet D (2008). Light-emitting diodes (LEDs) in dermatology. Semin Cutan Med Surg. Vol.27(4), pp.227-238.Link provided by the sponsor.
- Avci P., Gupta A, Sadasivam M, Vecchio D., Pam Z, Pam N., and Hamblin M.R. (2013). Low-level laser (light) therapy (LLLT) in skin: stimulating, healing, restoring. Semin Cutan Med Surg. Vol.32(1), pp.41-52 \[PubMed\]Link provided by the sponsor.
- Chung H, Dai T, Sharma SK, Huang YY, Carroll JD, Hamblin MR (2012). The nuts and bolts of low-level laser (light) therapy. Ann Biomed Eng. Vol.40 (2), pp.516-533.Link provided by the sponsor.
Related trials for Infertility
RecruitingObservational study
International Pilot Study for Dual Non-invasive Assesment of Embryo Development
Infertility
Active, not recruitingObservational study
Retrieval of Sperm From Men With Azoospermia Using Ultrasound-guided Rete Testis Aspiration
Azoospermia, Nonobstructive, Infertility, Male
Not yet recruiting
Spinery Basivertebral Nerve Ablation for Vertebrogenic Chronic Low Back Pain
Low Back Pain, Chronic Low Back Pain (CLBP)
RecruitingObservational study
Impact of Infertility on the Sexual Sphere in Couples Undergoing Assisted Reproduction
Sexual Health Quality of Life, Infertile Patients
RecruitingObservational study
Pilot Study of Discarded Blastocysts
Infertility (IVF Patients)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Amr H. El Noury, MD, FRCOG study director
Cairo University
Marwa A. El Shaer, MD study chair
Professor of Pathology at National Research Centre
Mona I. Morsy, MD study director
Lecturer in Molecular Biology in National Institute of Laser and Enhanced Science
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Low level Laser diode machine in people with Infertility, run by Cairo University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 25 Jul 2017. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Doaa A. El Faham, M.Sc. (010 95893624 ext. 002, drdody_as@hotmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Jul 2017.